| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082093 | Drug Discovery Today: Disease Models | 2012 | 8 Pages |
Abstract
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) represent a potential source of cells and tissues for regenerative medicine. Although hESCs are known to display some immune-privileged properties and patient-specific iPSCs have been expected to be ‘autologous’, post-transplantation rejection remains a major hurdle in the development of pluripotent stem cell (PSC)-based therapies. Here we describe the immunological barriers involved and approaches to promote the acceptance of PSC-derived grafts.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Gloria H. Tso, Jiaozi He, Camie W. Chan,